The product code (s) for this leaflet is: PLGB 13832/0042. Patient Leaflet (PIL) Medicine subjected to additional monitoring. com;What is Saxenda ®?. 2 mg and 1. Ozempic ® (semaglutide) injection 0. If you have any questions about this drug, please talk with your child’s doctor, nurse, pharmacist, or other health care provider. Semaglutide is the foundational molecule which serves as the primary ingredient for Novo Nordisk’s prescrip-tion-only, FDA-approved medicines: Wegovy ® (semaglutide) injection 2. (page 13-16) How to store Ozempic® (page 17-18) Contents of the pack and other information (page 19) Instructions on how to use Ozempic® 0. 4 milligrams, administered weekly as subcutaneous (under the skin) self-injections. It is a medicine that is used to lower blood sugar levels. S. wegovy® 0. Wegovy with Next-Day Delivery. This medicine is also used to lower the risk of heart attack, stroke, or death in patients with type 2 diabetes and heart or blood vessel disease. Risk of Thyroid C-cell Tumors. 8% of patients. The Patient Information Leaflet (PIL) is the leaflet included in the pack with a medicine. According to the patient information leaflet, this only affects around 1 in 100, so roughly 1% of Semaglutide users are likely to experience acute pancreatitis. It is used to lower blood sugar in patients with high blood sugar ( diabetes ). 7 mg and 2. Some drugs may have another patient information leaflet. If this patient would like to pursue pregnancy again, semaglutide 2. This leaflet is designed for people taking an oral GLP-1 (Semaglutide) for type 2 diabetes. 5 mg, 1 mg, or 2 mg is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus and to reduce the risk of major adverse cardiovascular (CV) events (CV death, nonfatal myocardial infarction, or nonfatal stroke) in adults with type 2 diabetes mellitus and. Call 1-833-275-2233 or visit RYBELSUS. Includes patient information for visually impaired in alternative formats. In the SUSTAIN 1 trial, 388 previously untreated patients were randomised to receive semaglutide (0. 7 mg and 2. Revised: 01/2020 WARNING: RISK OF THYROID C-CELL TUMORS See full prescribing information for complete boxed warning. 5mg solution for injection in pre-filled penConsumer Medicine Information (CMI) This leaflet provides important information about using Ozempic. solution for injection in pre-filled pen. 5. It is written by pharmaceutical companies as a patient version of the Summary of Product Characteristics (SPC). Semaglutide (Wegovy, Ozempic, Rybelsus) is a medicine used for weight loss in specific patients, and to lower blood sugar levels and reduce the risk of major cardiovascular events such as heart attack or stroke in type two diabetes patients. Caution should be exercised when using semaglutide in patients with diabetic retinopathy. 45–1. S. Take oral semaglutide once a day with a small glass of water (no more than 120mL) at least 30 minutes before the first food, beverage, or other oral drugs of the day. 4 mg is indicated as an adjunct to a reduced calorie diet and increased physical activity for chronic weight management in: adults with an initial body mass index (BMI) of ≥30 kg/m 2 (obesity) or ≥27 kg/m 2 (overweight) in the presence of at least one weight-related comorbid. lichen-planus. View semaglutide information, including dose, uses, side-effects, renal impairment, pregnancy, breast feeding,. semaglutide This medicine is subject to additional monitoring. 19, 95%CI [1. 4 mg is an injectable prescription medicine that may help adults and children aged ≥12 years with obesity (BMI ≥30 for adults, BMI ≥ 95th percentile for age and sex for children), or some adults with excess weight (BMI ≥27) (overweight) who also have weight-related medical. A greater number of patients in the semaglutide group achieved an HbA1c <7% compared with the liraglutide and placebo groups. 4 How do I use my Ozempic® pen? This is a Quick Guide. 1007/s13300-023-01506-1. Added INS186W. It is not used to treat type 1 diabetes (condition in which the body does not produce insulin and therefore cannot control the amount of sugar in the blood) or diabetic. Scientific reports about marketing authorisations for medicines. An increase in demand for the medicine has led to a shortage which is currently ongoing (for. How to store Saxenda® 6. Tear off the paper tab. Ozempic 0. semaglutide . Pen cap. See 17 for PATIENT COUNSELING INFORMATION and Medication Guide. Please talk to your healthcare provider about proper injection technique and follow instructions in the Instruction Leaflet that accompanies the pen. You're here: Patient Information Leaflets. 9% at 6 months. 5 Acute Gallbladder Disease 17. Revised: 01/2020 WARNING: RISK OF THYROID C-CELL TUMORS See full prescribing information for complete boxed warning. This includes any possible side effects not listed in the package leaflet. For full information, please make sure you read the Patient Information Leaflet provided with your Ozempic ® pen. SGLT2 inhibitors can, in rare cases lead to a. Clearance of semaglutide in patients with type 2 diabetes was approximately 0. Semaglutide 7/8 Healthcare Professionals (SmPC) Patient Leaflet (PIL) Letters to HCPs. It is similar to a natural hormone called glucagon-like peptide-1 (GLP-1) that is released from the intestine after a meal. 3. To initiate patients on oral semaglutide, it is recommended that a dose-escalation strategy be used, starting with 3 mg once daily for 30 days, then increasing to 7 mg once daily. What is in this leaflet. Viatris launched a non-interchangeable Semglee in 2020 at a WAC price of $99, marking a steep discount off Lantus' WAC of $284. (SEMAGLUTIDE TABLETS) This booklet is for patients who have been prescribed RYBELSUS®. Ozempic® (semaglutide) injection 0. Food and Drug Administration. When Semglee snagged its historic interchangeability tag in July. , a mass in the neck, dysphagia, dyspnea, persistent hoarseness). It can also reduce the risk of major cardiovascular events and help with weight loss. No dose adjustment is required for patients with hepatic impairment (see section 5. 18 October 2013See the end of this Patient Information leaflet for a complete list of ingredients in ENTRESTO. Rybelsus is a medication that is used to lower blood sugar levels in type 2 diabetes patients and also a medication that can help with weight loss. If pancreatitis is suspected, Victoza and other potentially suspect drugs should be discontinued. Package leaflet: Information for the patient. Please compare the 'Leaflet prepared/revised date' towards the end of the leaflet to establish if there have been any changes. How to use Saxenda® 4. Do ensure that you have read the patient information leaflet to be fully aware of the all the side effects. Last updated on emc: 18 Sep 2023. 9%) in the placebo group (hazard ratio, 0. This will allow quick identification of new safety information. This can help with blood glucose levels. You can help by reporting any side effects you may get. 8 and 4. A 12-week long trial was carried out on 415 subjects to find the optimal dose of semaglutide. the human relevance of semaglutide-induced rodent thyroid C-cell tumors has not been determined (5. unknown whether semaglutide causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans, as human relevance could not be ruled out by clinical or nonclinical studies. Check the Ozempic® flow with each new pen. 4 mg is an injectable prescription medicine used for adults with obesity (BMI ≥30) or overweight (excess weight) (BMI ≥27) who also Rybelsus® (semaglutide tablets) Product Monograph Page 33 of 39 PATIENT MEDICATION INFORMATION READ THIS FOR SAFE AND EFFECTIVE USE OF YOUR MEDICINE PRRYBELSUS® semaglutide tablets Read this carefully before you start taking Rybelsus® and each time you get a refill. Store unopened packs of liraglutide in a fridge. If you have any doubts or queries about. 4 mg solution for injection in pre-filled pen semaglutide. Semaglutide, a glucagon like peptide-1 (GLP-1) receptor agonist, is available as monotherapy in both subcutaneous as well as oral dosage form (first approved oral GLP-1 receptor agonist). 2022 Semaglutide Solution for injection [Weight Management] What is this medication? SEMAGLUTIDE (SEM a GLOO tide) promotes weight loss. Glucagon-like peptide 1 (GLP-1) is an incretin hormone that is released during a meal. patients with semaglutide. semaglutide (rys) 0. Package leaflet: Information for the patient. Wegovy™ (semaglutide injection) Product Monograph Page 31 of 54 READ THIS FOR SAFE AND EFFECTIVE USE OF YOUR MEDICINE . Semaglutide is highly efficacious, with the majority of patients experiencing clinically significant weight. For patients considered overweight or with obesity, we treat with semaglutide injections at the maximum dose (2. The primary outcome occurred in 108 of 1648 patients (6. Semaglutide (Ozempic ®) is one such modified human GLP-1 analogue, which has been developed by Novo Nordisk for the treatment of type 2 diabetes mellitus. Read the Instructions for Use and Important Safety Information before using the pen. 0–8. 5mg solution for injection in pre-filled penSemaglutide injection (Ozempic) is also used to reduce the risk of a stroke, heart attack, or death in adults who have type 2 diabetes along with heart and blood vessel disease. Who can and cannot take it. In patients with diabetic retinopathy treated with insulin and s. We hope that you have found this information useful. However, diastolic blood. 1). With an elimination half-life of approximately 1. † Regulations require you to enter your drug identification number (DIN) to access content that is intended only for patients who have been prescribed Ozempic ® . You can help by reporting The Patient Information Leaflet (PIL) is the leaflet included in the pack with a medicine. 05 L/h. It helps your body reduce your blood sugar level only when blood sugar is too high and can help prevent heart disease. 5 mg solution for injection in pre-filled pen. Pancreatitis: Has been reported in clinical trials. Use this medicine (semaglutide tablets) as ordered by your doctor. 0845 600 5055 Calls may be recorded for training purposes Office hours 8. Food and Drug Administration today approved Rybelsus (semaglutide) oral tablets to improve control of blood sugar in adult patients with type 2 diabetes, along with. It stimulates glucose-dependent. 7 mg once weekly. Please see the Patient Information Leaflet for full information. Companies. 5 mg and 1 mg in Patients with Type 2 Diabetes and Cardiovascular Disease . The text only version may be available in large print, Braille or audio CD . Learn More GLP-1 RA=glucagon-like peptide-1 receptor agonist. For patients unable to tolerate this dose, lower doses can be used as long as ≥5 percent weight loss is achieved (see 'Dosing' below). 22 Semaglutide is a GLP-1 receptor agonist (GLP-1RA). It is useful to complement these findings with real-world evidence. Use in renal impairment Experience with the use of semaglutide in patients with severe (CrCL < 30 mL/min) renal impairment is limited. How and when to take it. Currently, the Semaglutide patient information leaflet states that if you have any of the following conditions, you should either avoid the medication or speak to your own GP before using the weekly injection: Allergic to any of the ingredients in the semaglutide injection; Type 1 diabetes; Diabetic ketoacidosis;Scroll to ISI What is Wegovy ®?. 8 mg without dose escalation, or doses of 0. 4 mg is indicated as an adjunct to a reduced calorie diet and increased physical activity for chronic weight management in: adults with an initial body mass index (BMI) of ≥30 kg/m 2 (obesity) or ≥27 kg/m 2 (overweight) in the presence of at least one weight-related comorbid. Active Ingredients. Consumer Medicine Information (CMI) summary The . This medicine is subject to additional monitoring. : Oral semaglutide was found to be safe and well tolerated across all phase III trials with the main adverse reactions being nausea, vomiting, and diarrhea, similar to the. Your doctor or nurse will show you how to take it. to reduce the risk of major cardiovascular events such as heart attack, stroke, or death in adults with type 2 diabetes with known heart disease. The most common side effects with Rybelsus affect the digestive system; the side effects are generally manageable and similar to those with an authorised injectable form of semaglutide (Ozempic). 8 mg doses of daily-once liraglutide, or placebo. 2. 17. 8). Conclusions. ThePackage leaflet: Information for the patient . 5 mg once weekly. You can help by reporting any side effects you may get. Package leaflet: Information for the patient . It is not used to treat type 1 diabetes (condition in which the body does not produce insulin and therefore cannot control the amount of sugar in the blood) or diabetic. Counsel patients regarding the potential risk of MTC and symptoms of thyroidWegovy is available as pre-filled pens containing a solution for injection. Subcutaneous (SC) semaglutide (Ozempic®) is a GLP-1RA with an extended half-life of approximately 1. Wegovy® (semaglutide) injection 2. Print patient leaflet as text only. As the drugs cause more glucose to be excreted in the urine, there is a higher chance of getting genital and urinary tract infections These side effects are more common in women than in men. Where can I find my DIN? Enter. Side effects. The MHRA products website allows you to find: The leaflets which are provided with medicines. You can help by reporting any side effects you may get. 81% (SD 0. , prediabetes, hypertension, and obstructive sleep apnea). Adults with an average starting A1C of 8. Due to regulatory changes, the content of the following Patient Information Leaflet may vary from the one found in your medicine pack. GLP-1 RA. Studies show semaglutide helps 66-84 per cent of people who use the drug to lose weight, making it more effective than other drugs on the market After two years, patients using it still benefit by. The text only version may be available in large print, Braille or audio CD . 77%) compared with liraglutide (0. Ozempic ® (semaglutide) injection 0. 96 mmol/mol (1. 55%) after 30 weeks. It is given once every week (every 7 days). 4. When taking Semaglutide, it can sometimes be difficult to tell whether you’re experiencing common side effects or if you’re developing pancreatitis. This is the official leaflet for wegovy, a medicine for weight loss and weight maintenance that contains semaglutide. Question Is treatment with semaglutide associated with weight loss outcomes similar to those seen in results of randomized clinical trials?. Please always ensure that you read the patient information leaflet. 1 day ago · check the Patient Information Leaflet for Ozempic and Patient Information Leaflet for Saxenda to clarify what the genuine pens look like. Patients can administer the medicine themselves. Ozempic helps to regulate appetite and make you feel less hungry by. This medicine is available only with your doctor's prescription. Print Save Semaglutide (Oral) Generic name: semaglutide [ sem-a-GLOO-tide ] Drug class: Incretin mimetics Medically reviewed by Drugs. Showing a reduction of 15. Limitations of Use. Important information If you notice severe, persistent abdominal pain, contact your GP. 7 mg and 2. According to Caroline Messer, MD, a board-certified. Ozempic ® is contraindicated in patients with a personal or family history of MTC or in patients with MEN 2, and in patients with known hypersensitivity to semaglutide or to any of the product components. Dose counter. What should I know before I. Wegovy ® (semaglutide) injection 2. 101-2476 Argentia Road. 20 Briefly, in total, 3297 patients were randomized 1:1:1:1 to receive once‐weekly s. It may also be. Eye-catching results. Clearance of semaglutide in patients with type 2 diabetes was approximately 0. 0. See the end of section 4 for how to report side effects. With an elimination half-life of approximately 1. 8%). The consolidation of the 4 trials also showed that patients given semaglutide were twice as likely to discontinue treatment due to adverse events (RR 2. In the PIONEER 5 trial, once-daily oral semaglutide 14 mg was superior to placebo in decreasing HbA1c and body weight in DKD patients with an eGFR of 30–59 mL/min/1. This leaflet is a summary and will not tell you everything about this drug. Last updated on emc: 18 Sep 2023. wegovy FlexTouch. 1). Take with no more than 4 ounces of plain water. † Regulations require you to enter your drug identification number (DIN) to access content that is intended only for patients who have been prescribed Ozempic ® . Gently pull the syringe out of the skin. Patient Information Leaflet: For more information on the medication please refer to the patient information leaflet for Wegovy. What Saxenda® is and what it is used for . 4 mg. Children younger than 12 years of age—Use and dose must be determined by your doctor. 8, 1. Ozempic® (semaglutide) injection 0. The text only version may be available in large print, Braille or audio CD . 25 mg or 0. The product code (s) for this leaflet is: PL 17901/0064. 5 mg or 1 mg) or a placebo. According to the patient information leaflet, this only affects around 1 in 100, so roughly 1% of Semaglutide users are likely to experience acute pancreatitis. Semaglutide injection is used to treat type 2 diabetes. Consumer Medicine Information (CMI) This leaflet provides important information about using Ozempic ®. 0 mg) or oral semaglutide (14 mg) given as monotherapy were able to reduce HbA 1c by. 4, 0. Tips. Using a slow and constant pressure, push the plunger rod until it reaches the bottom. Semaglutide This information from Lexicomp explains what you need to know about this medication, including what it’s used for, how to take it, its side effects, and when to call your healthcare provider. Individually, the risk for discontinuation due to adverse events is 6% for semaglutide group and 2. Currently, the Semaglutide patient information leaflet states that if you have any of the following conditions, you should either avoid the medication or speak to your own GP before using the weekly injection: Allergic to any of the ingredients in the semaglutide injection; Type 1 diabetes; Diabetic ketoacidosis;Scroll to ISI What is Wegovy ®?. Recommendation: GREEN (restricted) as an alternative GLP-1 receptor agonist for patients who are unable to use subcutaneous formulations or patients who prefer oral administration. Semaglutide (Ozempic®) should be injected once weekly at any time of the day, with or. c. The active ingredient in Rybelsus is called semaglutide. 5 mg, 1 mg, 1. Among its multifaceted functions is the ability to connect the absorption of nutrients from the gastrointestinal tract with pancreatic hormone secretion. Brand Names: US Ozempic (0. It is injected once a week under the skin in the belly, thigh or upper arm. Do ensure that you have read the patient information leaflet to be fully aware of the all the side effects. 5 mg, 1 mg, or 2 mg For adult patients with type 2 diabetes (T2D), treated with diet and exercise to improve glycemic control, and to reduce the risk of major adverse cardiovascular events (cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke) in adults with T2D and established cardiovascular disease. Experience with the use of semaglutide in patients with severe hepatic impairment is limited. Indication and Usage. • have had an allergic reaction including swelling of your face, lips, tongue, throat , or trouble breathing while taking a type. Below is a text only representation of the Patient Information Leaflet (ePIL). 1 Pharmacodynamic Properties and 5. You can help by reporting any side effects you may get. To date, the most. Patient Counseling Information. may have beneficial effects on blood pressure; though the effect of GLP 1 medication semaglutide in obese patients and patients with hypertension (high blood pressure) is undetermined as yet. Liraglutide is given once a day as an injection just under the surface of the skin. com. package leaflet. A. Serious hypersensitivity reactions, including anaphylaxis and angioedema have been reported with semaglutide. The MHRA added that Ozempic is a “black triangle medicine”, meaning that, as a new drug, it is more closely monitored and, consequently, all suspected adverse reactions, even those from the. 3). 25 milligrams (mg) injected under the skin once a week for 4 weeks. Semaglutide is used to treat type 2 diabetes. 0845 600 5055 Calls may be recorded for training purposes Office hours 8. Due to highly variable absorption, the manufacturer estimates 2-4% of patients may not respond to oral semaglutide. Please always ensure that you read the patient information leaflet accompanying your medication. semaglutide . Clinical Guidelines. 3. g. Read Important Safety Information. 6 November 2013. The NHS is currently facing supply issues with glucagon-like peptide receptor agonists (GLP-1 RAs), a range of drugs used for managing blood glucose levels in people with type 2 diabetes . 0001 for all comparisons). . Type in the name of the medicine in the search box and select submit. Many prescribe other brands of semaglutide, such as Ozempic and Rybelsus, off-label (using. Search for information about medicines including patient information leaflets (PILs), details on how the medicine can be used (SmPCs) and scientific reports (PARs). (). Search for information about medicines including patient information leaflets (PILs), details on how the medicine can be used (SmPCs) and scientific reports (PARs). Common side effects include low blood sugar levels, nausea, vomiting, and diarrhea. 5 mg or 1 mg is an injectable prescription medicine used: • along with diet and exercise to improve blood sugar in adults with type 2. See 17 for PATIENT COUNSELING INFORMATION and Medication Guide. This medicine is subject to additional monitoring. Once in use, you can keep the pre-filled pen for up to 30 days at room temperature. 25mg solution for injection in pre-filled pen; Ozempic 0. Body weight significantly decreased at 6 months after the start of oral semaglutide, and serum uric acid (UA) levels showed a significant decrease after 3 months. Changes in metabolic parameters after the start of oral semaglutide in patients who switched from GLP-1 analogues are shown in Table 4. Indications and Usage. 0%) compared to placebo (1. Patient Information Leaflet: For more information on the medication please refer to the patient information leaflet for Ozempic. Wait 30 minutes before eating, drinking, or taking other oral medications. Patients should be advised to read the instruction for use included in the package leaflet carefully before administering the medicinal product. See the end of. What is Wegovy™? Wegovy™ (semaglutide) injection 2. Ozempic is a prescription medicine that contains semaglutide, a substance that helps lower blood sugar levels in adults with type 2 diabetes. Findings In this cohort study of 175 patients with overweight or obesity, the total body weight loss percentages achieved were 5. Liraglutide is given once a day as an injection just under the surface of the skin. This medication should not be used as a substitute for insulin, and it is important to. 54 mmol/mol (8. 7 mg and 2. 1) and Nonclinical Toxicology (13. 1 Important Administration Instructions Semaglutide is contraindicated in patients with a personal or family history of MTC or in patients with MEN 2. Glucagon-like peptide 1 receptor agonists (GLP-1RAs) are being investigated to slow the decline of kidney function in type 2 diabetics with chronic kidney disease (CKD). injection in pre-filled pen. A Patient Information Leaflet (PIL) is the leaflet for patients containing information on taking a medicine, that is included with the medicine [email protected] Semaglutide is a GLP-1 receptor agonist (GLP-1RA). Pediatric Patients Aged 12 Years and Older. To learn more about Wegovy and how it can. If you have questions or concerns be sure to contact your Healthcare. See the end of section 4 for how to report side effects. Ozempic ® (semaglutide) injection 0. Semaglutide (4,113. 2 Instructions 17. Please see the Patient Information Leaflet for full information. Ozempic is a product information document that provides detailed information on the medicine semaglutide, which is used to treat type 2 diabetes. . BAD Video Library. Dulaglutide and subcutaneous semaglutide are longer-acting compounds that require once-weekly administration [22, 23]. For more information, see Section . Semaglutide injection is used to treat type 2 diabetes. 2. Wegovy (Semaglutide) through. 1, 13. semaglutide of variable doses ranging from 0. What Saxenda® is and what it is used forINS186 PDF leaflet updated. We hope that you have found this information useful. Download a digital Patient Starter Kit. This website provides reliable, evidence-based, and accurate information about use of medicines in pregnancy, in the form of freely available patient information leaflets called 'Bumps' ('Best Use. The remaining 16 patients were included in this. The absolute risk increase for diabetic retinopathy complications was larger among. Possible side effects . It is very important that your doctor check your progress at regular visits to make sure that this medicine is working properly. Dulaglutide (~ 63,000 Da) is derived from two modified GLP-1 molecules attached to an Fc fragment of immunoglobulin G and has a half-life of ~ 5 days []. 4 mg once a week. SEMGLEE pen is a disposable single-patient-use prefilled insulin pen. A Patient Information Leaflet (PIL) is the leaflet for patients containing information on taking a medicine, that is included with the medicine packaging. The kit provides answers to questions about starting Ozempic ® and pen use, plus information on diet and exercise. The description of the medicinal product’s properties and how it can be used. You can help by reporting any side effects you may get. The text only version may be available in large print, Braille or audio CD . 1%, the highest doses of subcutaneous semaglutide (1. Novo Nordisk Limited via . 8). 001 events/patient year) were observed with semaglutide in combination with oral antidiabetics other than sulfonylurea. Ozempic® (semaglutide) injection 0. Semaglutide (Wegovy, Ozempic, Rybelsus) is a medicine used for weight loss in specific patients, and to lower blood sugar levels and reduce the risk of major. Your doctor may order certain tests to check your body's response to semaglutide. n engl j med 384;11 nejm. 96 mmol/mol (1. 9% at 3 months and 10. 45–1. Ozempic® contains the active substance semaglutide. Alternatively, click here for the Semaglutide 1. Where to find information in this leaflet: 1. RYBELSUS ® has not been studied in patients with a history of pancreatitis. Text HELP to 21848 for help. patients at risk of running out of Ozempic® are safely switched to another glucagon-like peptide-1 receptor agonist or other suitable alternatives based on your clinical judgement) • An alternative form of semaglutide; Rybelsus (oral semaglutide) is currently available in. 3 . 8%). Patients should only obtain drugs containing semaglutide with a prescription from a licensed health care provider, and only obtain medicines from state-licensed pharmacies or outsourcing facilities registered with the FDA. solution for injection in pre-filled pen. The glucagon-like peptide-1 receptor agonist (GLP-1RA) semaglutide is the most recently approved agent of this drug class, and the only GLP-1RA currently available as both subcutaneous and oral formulation. • Wegovy™ contains semaglutide and should not be used with other semaglutide-containing products or other GLP-1 receptor agonist medicines. 1% of subjects, 0. Semaglutide (Ozempic®) is to be injected into the abdomen, thigh or upper arm. Experience with the use. Patients can administer the medicine themselves. manufacturer), and the specific batch -number. Resources for Canadian patients. It works by helping the pancreas to release the right amount of insulin when blood sugar levels are high. 74; 95% confidence interval [CI], 0.